Exubera Side Effects

Generic Name: insulin inhalation, rapid acting

Note: This page contains information about the side effects of insulin inhalation, rapid acting. Some of the dosage forms included on this document may not apply to the brand name Exubera.

Not all side effects for Exubera may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to insulin inhalation, rapid acting: inhalation aerosol powder

In addition to its needed effects, some unwanted effects may be caused by insulin inhalation, rapid acting (the active ingredient contained in Exubera). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking insulin inhalation, rapid acting:

More common
  • Anxiety
  • blurred vision
  • chills
  • cold sweats
  • coma
  • confusion
  • cool, pale skin
  • cough
  • depression
  • dizziness
  • fast heartbeat
  • headache
  • increased hunger
  • nausea
  • nightmares
  • seizures
  • shakiness
  • slurred speech
  • unusual tiredness or weakness
Incidence not known
  • Difficulty breathing
  • difficulty swallowing
  • hives, itching, or skin rash
  • noisy breathing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • tightness in the chest

Some of the side effects that can occur with insulin inhalation, rapid acting may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Diarrhea
  • sore throat
Incidence not known
  • Weight gain

For Healthcare Professionals

Applies to insulin inhalation, rapid acting: inhalation powder

Respiratory

In clinical trials of up to 2 years duration, a 15% or greater reduction in forced expiratory volume (FEV1) occurred in 6% of patients treated with inhaled insulin compared with a 3% decline in patients receiving comparator anti-diabetes treatment. Patients with chronic lung disease were not included in these studies. The FEV1 decline occurred during the first 3 months and persisted; it did not appear to worsen with increased duration of use. The changes in FEV1 were similar in patients with type 1 and type 2 diabetes mellitus.

Very common (10% or more): Cough (25.6% to 29.4%)
Common (1% to 10%): Bronchitis, productive cough, decreased pulmonary function test

Metabolic

Very common (10% or more): Hypoglycemia, non-severe (67%)
Common (1% to 10%): Hypoglycemia, severe
Uncommon (0.1% to 1%): Diabetic ketoacidosis
Frequency not reported: Weight gain

Diabetic ketoacidosis:
In patients with type 1 diabetes, diabetic ketoacidosis occurred in 0.43% (n= 13) of patients who received inhaled insulin compared with 0.14% (n=3) of patients receiving subcutaneous insulin.

Hypoglycemia:
The incidence of non-severe hypoglycemia in patients with type 2 diabetes was 67%. The incidence of severe hypoglycemia was reported at 5.1%. A severe episode was defined as a hypoglycemic event requiring assistance of another person and associated with either a blood glucose value consistent with hypoglycemia or prompt recovery following treatment. A non-severe episode was defined as symptoms of hypoglycemia with or without a low blood glucose value. The incidence of hypoglycemia was not reported for patients with type 1 diabetes.

Weight gain:
In patients with type 2 diabetes mellitus who received inhaled insulin therapy, a mean weight gain of 0.49 kg occurred compared with a mean weight loss of 1.13 kg in placebo-treated patients.

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea

General

The most common adverse reactions reported included hypoglycemia, cough, throat pain or irritation.

The most common reason for drug discontinuation was cough.

Local

Common (1% to 10%): Throat pain or irritation

Genitourinary

Common (1% to 10%): Urinary tract infection

Oncologic

During clinical trials, 2 cases of lung cancer were reported; in both cases, heavy tobacco use was reported. Following completion of clinical trials, 2 cases of squamous cell lung cancer were reported in non-smokers.

Frequency not reported: Lung cancer

Other

Common (1% to 10%): Fatigue

Psychiatric

Common (1% to 10%): Headache

More about Exubera (insulin inhalation, rapid acting)

Consumer resources

Professional resources

Related treatment guides

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)